Crystalline forms of a pharmaceutical compound
AssigneeH. Lundbeck A/S
InventorsMichael Rock, Heidi Lopez De Diego, Kim Christensen, Ole Nielsen, Anders Buur, Mark Howells
Life of this patent
Estimating the term…
Abstract
Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
Claims54
Crystalline Compound I, which compound has the formula
Solid Compound I containing crystalline Compound I alpha form, wherein Compound I has the formula
Solid Compound I containing crystalline Compound I beta form, wherein Compound I has the formula
Solid Compound I containing crystalline Compound I gamma form, wherein Compound I has the formula
Solid Compound I containing crystalline Compound I delta form, wherein Compound I has the formula
Solid Compound I containing crystalline Compound I epsilon form, wherein Compound I has the formula
A method for preparing crystalline Compound I, comprising forming crystalline Compound I in a solvent of methanol with 0% to about 8% water, wherein Compound I has the formula
A method for the manufacturing of Compound I, which method comprises a step of converting Compound I to crystalline Compound I, wherein Compound I has the formula
A method for the manufacturing of a pharmaceutical composition of Compound I which method comprises preparing said composition from crystalline Compound I, wherein Compound I has the formula
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.